Navigation Links
Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661231/Osteoarthritis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.

- Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals,LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global osteoarthritis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Osteoarthritis Therapeutics: Executive Summary 9

2.1 The Osteoarthritis Therapeutics Market is Forecast to Show Slow Growth until 2018 9

2.2 The Osteoarthritis Therapeutics Market has Significant Unmet Need 10

2.3 Scope for Entrants with Better Efficacy and Safety Profiles 10

2.4 Late Stage Pipeline Lacks DMOADs and Does Not Offer Hope for OA Patients 11

3 Osteoarthritis Therapeutics: Introduction 12

3.1 Overview 12

3.2 Epidemiology 12

3.3 Etiology and Pathophysiology 13

3.4 Risk Factors 15

3.5 Symptoms 16

3.6 Diagnosis of OA 16

3.6.1 Clinical History 16

3.6.2 Physical Examination 16

3.6.3 Diagnostic Imaging Techniques 17

3.7 Treatment 17

3.7.1 Non-Pharmacological Therapy 18

3.7.2 Pharmacological Therapy 19

3.7.3 Surgical Treatment 20

3.8 GlobalData Pipeline Report Guidance 21

4 Osteoarthritis Therapeutics: Market Characterization 23

4.1 Major Markets, Market Size (2005-2010) 23

4.2 Major Markets, Market Forecast (2010-2018) 25

4.3 OA Therapeutics Market Size (2005-2010) – The US 27

4.4 OA Therapeutics Market Forecast (2010-2018) – The US 29

4.5 OA Therapeutics Market Size (2005-2010) – The UK 30

4.6 OA Therapeutics Market Forecast (2010-2018) – The UK 32

4.7 OA Therapeutics Market Size (2005-2010) – France 33

4.8 OA Therapeutics Market Forecast (2010-2018) – France 34

4.9 OA Therapeutics Market Size (2005-2010) – Germany 36

4.10 OA Therapeutics Market Forecast (2010-2018) – Germany 37

4.11 OA Therapeutics Market Size (2005-2010) – Italy 38

4.12 OA Therapeutics Market Forecast (2010-2018) – Italy 40

4.13 OA Therapeutics Market Size (2005-2010) – Spain 41

4.14 OA Therapeutics Market Forecast (2010-2018) – Spain 43

4.15 OA Therapeutics Market Size (2005-2010) – Japan 44

4.16 OA Therapeutics Market Forecast (2010-2018) – Japan 45

4.17 Drivers and Barriers for the OA Therapeutics Market 47

4.17.1 Drivers for the OA Therapeutics Market 47

4.17.2 Barriers for the OA Therapeutics Market 47

4.18 Key Events Impacting the Future Market 48

4.19 Opportunity and Unmet Need 49

4.20 Key Takeaway 50

5 OA Therapeutics Market: Competitive Assessment 51

5.1 Overview 51

5.1.1 Strategic Competitor Assessment 51

5.2 Profiles of Commonly Used Products in the OA Therapeutics Market 52

5.2.1 Celebrex (celecoxib) 52

5.2.2 Cymbalta (duloxetine hydrochloride) 53

5.2.3 Hyalgan (sodium hyaluronate) 54

5.2.4 Nucynta (tapentadol) 55

5.2.5 Voltaren Gel (diclofenac sodium topical gel 1%) 56

5.3 Key Takeaway 57

6 OA Therapeutics Market: Pipeline Assessment 58

6.1 Overview 58

6.2 Strategic Pipeline Assessment 58

6.2.1 OA Therapeutics – Molecules in Pre-Registration 60

6.2.2 OA Therapeutics – Phase III Pipeline 60

6.2.3 OA Therapeutics – Phase II/III Pipeline 61

6.2.4 OA Therapeutics – Phase II Pipeline 61

6.2.5 OA Therapeutics – Phase I/II Pipeline 62

6.2.6 OA Therapeutics – Phase I Pipeline 62

6.2.7 OA Therapeutics – Preclinical Pipeline 63

6.2.8 OA Therapeutics – Discovery Pipeline 64

6.3 OA Pipeline by Mechanism of Action 65

6.4 OA Technology Trends Analytical Framework 67

6.5 OA Therapeutics – Promising Drugs under Clinical Development 69

6.6 Molecule Profile for Promising Drugs under Clinical Development 70

6.6.1 Cartistem 70

6.6.2 Civanex (civamide, zucapsaicin) 70

6.6.3 Strontium Chloride Hexahydrate (2PX) 71

6.6.4 Oral Salmon Calcitonin (SMC021) 72

6.6.5 BEMA Buprenorphine 72

6.6.6 IP 880 and IP 889 73

6.7 Key Takeaway 73

7 Osteoarthritis Therapeutics – Clinical Trials Mapping 74

7.1 Clinical Trials by Country (US, EU5 and Japan) 74

7.2 Clinical Trials by Phase 75

7.3 Clinical Trials by Trial Status 76

7.4 Prominent Sponsors 77

7.5 Top Companies Participating in OA Therapeutics Clinical Trials 80

8 Osteoarthritis Therapeutics: Strategic Assessment 82

8.1 Osteoarthritis Therapeutics: Implications for Future Market Competition 82

9 Osteoarthritis Therapeutics: Future Players in the Market 84

9.1 Introduction 84

9.1.1 BioDelivery Sciences International 84

9.1.2 Cephalon, Inc. 86

9.1.3 Iroko Pharmaceuticals, LLC 88

9.1.4 Novartis AG 89

9.1.5 SantoSolve AS 91

9.1.6 Winston Pharmaceuticals, Inc. 92

9.1.7 Other Companies in Osteoarthritis Therapeutics Market 92

10 OA Therapeutics: Licensing and Partnership Deals 95

11 Osteoarthritis Therapeutics: Appendix 98

11.1 Definitions 98

11.2 Acronyms 98

11.3 Research Methodology 99

11.3.1 Coverage 100

11.3.2 Secondary Research 100

11.3.3 Forecasting 100

11.3.4 Primary Research 103

11.3.5 Expert Panel Validation 104

11.4 Contact Us 104

11.5 Disclaimer 104

11.6 Bibliography 105

List of Tables

Table 1: Osteoarthritis – Prevalence, Major Markets, 2010 15

Table 2: Surgical Procedures for Osteoarthritis 23

Table 3: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005–2010 26

Table 4: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010–2018 28

Table 5: OA Therapeutics Market, The US, Revenue ($bn), 2005–2010 30

Table 6: OA Therapeutics Market, The US, Forecast ($bn), 2010–2018 32

Table 7: OA Therapeutics Market, The UK, Revenue ($m), 2005–2010 33

Table 8: OA Therapeutics Market, The UK, Forecast ($m), 2010–2018 35

Table 9: OA Therapeutics Market, France, Revenue ($m), 2005–2010 36

Table 10: OA Therapeutics Market, France, Forecast ($m), 2010–2018 37

Table 11: OA Therapeutics Market, Germany, Revenue ($m), 2005–2010 39

Table 12: OA Therapeutics Market, Germany, Forecast ($m), 2010–2018 40

Table 13: OA Therapeutics Market, Italy, Revenue ($m), 2005–2010 41

Table 14: OA Therapeutics Market, Italy, Forecast ($m), 2010–2018 43

Table 15: OA Therapeutics Market, Spain, Revenue ($m), 2005–2010 44

Table 16: OA Therapeutics Market, Spain, Forecast ($m), 2010–2018 46

Table 17: OA Therapeutics Market, Japan, Revenue ($m), 2005–2010 47

Table 18: OA Therapeutics Market, Japan, Forecast ($m), 2010–2018 48

Table 19: OA Therapeutics – Molecules in Pre-Registration 62

Table 20: OA Therapeutics – Phase III Pipeline 63

Table 21: OA Therapeutics – Phase II/III Pipeline 63

Table 22: OA Therapeutics – Phase II Pipeline 64

Table 23: OA Therapeutics – Phase I/II Pipeline 64

Table 24: OA Therapeutics – Phase I Pipeline 65

Table 25: OA Therapeutics – Preclinical Pipeline 66

Table 26: OA Therapeutics – Discovery Pipeline 67

Table 27: Other Mechanisms of Action from Figure 29 69

Table 28: OA Therapeutics – Promising Drugs Under Clinical Development, 2011 71

Table 29: OA Therapeutics – Clinical Trials by Country, 2011 76

Table 30: OA Therapeutics – Clinical Trials by Phase, 2011 77

Table 31: OA Therapeutics – Clinical Trials by Status, 2011 78

Table 32: OA Therapeutics, Overall Sponsors, 2011 80

Table 33: OA Therapeutics - Prominent Sponsors, 2011 82

Table 34: OA Therapeutics - Top Companies Participating in Clinical Trials, 2011 84

Table 35: BioDelivery Sciences International – Osteoarthritis Therapeutics Pipeline 89

Table 36: Cephalon, Inc. – Osteoarthritis Therapeutics Pipeline 91

Table 37: Iroko Pharmaceuticals, LLC – Osteoarthritis Therapeutics Pipeline 92

Table 38: Novartis AG – Osteoarthritis Therapeutics Pipeline 94

Table 39: SantoSolve AS – Osteoarthritis Therapeutics Pipeline 95

Table 40: Winston Pharmaceuticals, Inc. – Osteoarthritis Therapeutics Pipeline 95

Table 41: OA Therapeutics Market- Future Players 96

Table 42: OA Therapeutics: Licensing and Partnership Deals 98

List of Figures

Figure 1: OA Therapeutics Market, Major Markets, Revenue and Forecast ($bn), 2005-2018 11

Figure 2: Opportunity and Unmet Need in the OA Therapeutics Market, 2010 12

Figure 3: Aetiology and Pathophysiology of Osteoarthritis 16

Figure 4: Articular Structures Affected in Osteoarthritis 17

Figure 5: Osteoarthritis Treatment Overview 20

Figure 6: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005–2010 25

Figure 7: OA Therapeutics, Market Share ($m), 2010 26

Figure 8: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010–2018 27

Figure 9: OA Therapeutics, Market Share ($m), 2018 28

Figure 10: OA Therapeutics Market, The US, Revenue ($bn), 2005–2010 29

Figure 11: OA Therapeutics Market, The US, Forecast ($bn), 2010–2018 31

Figure 12: OA Therapeutics Market, The UK, Revenue ($m), 2005–2010 32

Figure 13: OA Therapeutics Market, The UK, Forecast ($m), 2010–2018 34

Figure 14: OA Therapeutics Market, France, Revenue ($m), 2005–2010 35

Figure 15: OA Therapeutics Market, France, Forecast ($m), 2010–2018 37

Figure 16: OA Therapeutics Market, Germany, Revenue ($m), 2005–2010 38

Figure 17: OA Therapeutics Market, Germany, Forecast ($m), 2010–2018 39

Figure 18: OA Therapeutics Market, Italy, Revenue ($m), 2005–2010 41

Figure 19: OA Therapeutics Market, Italy, Forecast ($m), 2010–2018 42

Figure 20: OA Therapeutics Market, Spain, Revenue ($m), 2005–2010 43

Figure 21: OA Therapeutics Market, Spain, Forecast ($m), 2010–2018 45

Figure 22: OA Therapeutics Market, Japan, Revenue ($m), 2005–2010 46

Figure 23: OA Therapeutics Market, Japan, Forecast ($m), 2010–2018 48

Figure 24: OA Therapeutics Market, Drivers and Restraints 2011 51

Figure 25: Opportunity and Unmet Need in the OA Therapeutics Market, 2011 52

Figure 26: OA Therapeutics – Strategic Competitor Assessment, 2011 54

Figure 27: OA Therapeutics - Pipeline by Phase of Clinical Development, 2011 61

Figure 28: OA Therapeutics Pipeline – DMOAD versus Symptomatic Relief, 2011 61

Figure 29: OA Market – Clinical Pipeline by Mechanism of Action, 2011 68

Figure 30: Technology Trends Analytical Framework of the OA Pipeline, 2011 70

Figure 31: Technology Trends Analytical Framework of the OA Pipeline - Description, 2011 71

Figure 32: OA Therapeutics – Clinical Trials by Country, 2011 76

Figure 33: OA Therapeutics – Clinical Trials by Phase, 2011 77

Figure 34: OA Therapeutics – Clinical Trials by Status, 2011 78

Figure 35: OA Therapeutics – Overall Sponsors, 2011 79

Figure 36: OA Therapeutics – Prominent Sponsors, 2011 81

Figure 37: OA Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 83

Figure 38: Implications for Future Market Competition in the Osteoarthritis Therapeutics Market, 2011 85

Figure 39: OA Therapeutics Market – Clinical Pipeline by Company , 2011 87

Figure 40: GlobalData Market Forecasting Model 105BioDelivery Sciences International

Cephalon, Inc.

Iroko Pharmaceuticals, LLC

Novartis AG

SantoSolve AS

Winston Pharmaceuticals, Inc.

To order this report:

Pathology Industry: Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis
2. Actress Jane Kaczmarek Teams Up With DePuy Orthopaedics to Launch Osteoarthritis Awareness and Education Program
3. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
4. Former NBA Star Allan Houston Joins "Apply Yourself!" Campaign to Raise Awareness of Osteoarthritis Hand and Knee Pain
5. The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI
6. Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
7. Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
8. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
9. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
10. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
11. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... Hermann Health System has teamed up with Houston Rockets, ... one-of-a-kind experience to pediatric patients at Children,s Memorial ... video and Google Cardboard, Howard was able to visit ... patients and their families an unexpected, and energetically received, ... video . Memorial Hermann IRONMAN Sports Medicine ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer the ... Specialists are the first office to be chosen by the dental implant manufacturer, Straumann, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
(Date:2/12/2016)... ... 12, 2016 , ... Nearly every health website and vision ... articles generally list between five and 15 foods that should be consumed regularly ... of these lists and believes that nutritious eye healthy foods are extremely important, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a ... CertainTeed, North America’s leading brand of building products, has improved upon its industry-best ... the mobile version of the ColorView® Exterior Style and Color Selector. Created expressly ...
(Date:2/12/2016)... Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... over the past 35 years. A president has access to health and wellness resources ... of the free world, no single individual has a schedule as frenetic as the ...
Breaking Medicine News(10 mins):